

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Roberto BURIONI

U.S. Serial No.: Not Yet Known, corresponding to  
International Application No.  
PCT/IT03/00032, filed January 29, 2003,  
which claims priority of Italian Serial  
No. RM2002A000049, filed January 30, 2002

Filed : Herewith

For : HUMAN MONOCLONAL ANTIBODY FAB FRAGMENTS  
DIRECTED AGAINST HCV E2 GLYCOPROTEIN AND  
ENDOWED WITH IN VITRO NEUTRALIZING  
ACTIVITY

Law Offices of Albert Wai-Kit Chan, LLC  
World Plaza, Suite 604  
141-07 20<sup>th</sup> Avenue  
Whitestone, NY 11357

July 22, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
Mail-Stop Patent Application

Sir/Madam:

INFORMATION DISCLOSURE STATEMENT

In accordance with his duty of disclosure under 37 C.F.R. §1.56, Applicant would like to direct the Examiner's attention to the following references which are listed below and on Form PTO/SB/08A and PTO/SB/08B (which are attached hereto as **Exhibit A**), and each individual reference further attached as **Exhibit 1** through 5.

1. PCT International Search Report for BURIONI, Roberto, Int'l Application No. PCT/IT03/00032, Filed January 29, 2003, Dated August 6, 2003. [**Exhibit 1**]

Applicant : Robert BURIONI  
U.S. Serial No.: Not Yet Known  
Filed : Herewith  
Page : 2

2. BURIONI, et al., "Nonneutralizing Human Antibody Fragments against Hepatitis C Virus E2 Glycoprotein Modulate Neutralization of Binding Activity of Human Recombinant Fabs." Virology, Vol. 288, 29-30 (2001). [Exhibit 2]
3. ALLANDER, et al., "Recombinant Human Monoclonal Antibodies against Different Conformational Epitopes of the E2 Envelope Glycoprotein of Hepatitis C Virus That Inhibit Its Interaction with CD81." Journal of General Virology, Vol. 81, 2451-2459 (2000). [Exhibit 3]
4. International Publication Number WO 00/05266 for Reiter, et al., Published February 3, 2000. "Anti Hepatitis C Virus Antibody and Uses Thereof". [Exhibit 4]
5. International Publication Number WO 02/055560 A2 for Schofield, et al., Published July 18, 2002. "Monoclonal Antibodies Specific for the E2 Glycoprotein of Hepatitis C Virus and Their Use in the Diagnosis, Treatment, and Prevention of Hepatitis C". [Exhibit 5]

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicant : Robert BURIONI  
U.S. Serial No.: Not Yet Known  
Filed : Herewith  
Page : 3

10/502307  
OT12 Rec'd PCT/PTO 22 JUL 2004

No fee is deemed necessary in connection with the filing of this IDS. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai Kit Chan

Albert Wai-Kit Chan  
Registration No. 36,479  
Attorney for Applicant  
Law Offices of  
Albert Wai-Kit Chan, LLC  
World Plaza, Suite 604  
141-07 20<sup>th</sup> Avenue  
Whitestone, New York 11357  
Tel: (718) 357-8836  
Fax: (718) 357-8615  
e-mail: kitchanlaw@aol.com

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

**(Use as many sheets as necessary)**

Sheet	1	of	2
-------	---	----	---

Application Number	Not Yet Known
Filing Date	Herewith
First Named Inventor	BURIONI, Roberto
Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	937-PCT-US

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
	4	WO 00/05266	02-03-2000	Reiter, et al.		
	5	WO 02/055560 A2	07-18-2002	Schofield, et al.		

Date  
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	Not Yet Known
		Filing Date	Herewith
		First Named Inventor	BURIONI, Roberto
		Art Unit	Not Yet Known
		Examiner Name	Not Yet Known
		Attorney Docket Number	937-PCT-US

Sheet	2	of	2
-------	---	----	---

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	PCT International Search Report for BURIONI, Roberto, Int'l Application No. PCT/IT03/00032, Filed January 29, 2003, Dated August 6, 2003	
	2	BURIONI, et al., "Nonneutralizing Human Antibody Fragments against Hepatitis C Virus E2 Glycoprotein Modulate Neutralization of Binding Activity of Human Recombinant Fabs." Virology, Vol. 288, 29-30 (2001)	
	3	ALLANDER, et al., "Recombinant Human Monoclonal Antibodies against Different Conformational Epitopes of the E2 Envelope Glycoprotein of Hepatitis C Virus That Inhibit Its Interaction with CD81." Journal of General Virology, Vol. 81, 2451-2459 (2000)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.